What Undetectable Minimal Residual Disease (uMRD) Means for Your CLL Prognosis
Updated on July 16, 2026
ON THIS PAGE
ON THIS PAGE
A key question you’ll likely have after chronic lymphocytic leukemia (CLL) treatment is how well it worked. At that point, your care team may mention “remission,” which means there’s no sign of cancer in your tests and no physical symptoms of leukemia. But remission doesn’t always mean that every cancer cell is gone. Even if you don’t have symptoms, some cancer cells may still be present, and routine tests may not pick them up. Doctors call these remaining cells minimal (or measurable) residual disease (MRD).
In some cases, your care team may say you’ve achieved “undetectable MRD” (uMRD). This means that even with highly sensitive tests, they can’t find any remaining CLL cells in your blood or bone marrow, says James McCloskey, MD, chief of the division of leukemia at John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.
Although achieving uMRD doesn’t mean a full cure for your CLL, it’s a crucial sign that treatment has been highly effective and is often associated with better long-term outcomes. Here’s what to know about uMRD and what it might mean for the road ahead.
How Doctors Look for uMRD
Using a microscope, a healthcare professional who examines cells, tissue samples, and body fluids to help diagnose diseases (a pathologist) can identify about one cancer cell among 100 cells.
MRD testing casts a finer net, capable of detecting one abnormal cell within a population of 10,000 and, in some cases, even one cell out of a million, says Adam Cloe, MD, a board-certified hematopathologist at Los Angeles General Medical Center in California and a member of the College of American Pathologists.
Two main methods used to test for MRD are flow cytometry and next-generation sequencing, and a pathologist can perform both using a blood or a bone marrow sample. These tests identify CLL cells in different ways, and they have varying sensitivity levels.
Flow Cytometry
Flow cytometry acts like a cell sorter. It uses a laser to identify CLL cells by their unique surface proteins. Dr. McCloskey compares it to shining a special light over a jar filled with millions of white beads (representing healthy cells) mixed with a few red ones (CLL cells). The light makes only the red beads glow, allowing the machine to find and count them precisely.
This highly reliable and widely available test can detect about one abnormal cell per 10,000 healthy cells.
Next-Generation Sequencing
Instead of looking at cells’ surfaces, next-generation sequencing searches for their unique DNA. It zeroes in on specific sections of DNA found in CLL cells and makes copies of that genetic signal, so that even tiny amounts become detectable, Dr. Cloe says
“It identifies the unique genetic ‘barcode’ of your specific CLL cells and then scans millions of cells to find any trace of that exact barcode, making it an even more sensitive method [than flow cytometry],” explains McCloskey. That usually means your cancer care team will need to collect a tumor sample before treatment to establish that genetic barcode.
Your care team may say you’ve achieved uMRD when these tests find fewer than one CLL cell per 10,000 white blood cells in your sample.
What Achieving uMRD Means for Your Prognosis
Achieving uMRD is a reliable sign that treatment worked as well as it could, and it indicates a much lower risk of the leukemia becoming active again, says McCloskey. While other factors, such as genetic biomarkers, age, and overall health, also influence your prognosis, here’s why doctors consider uMRD such a significant milestone.
Longer Progression-Free Survival
One meaningful way doctors measure treatment success is through progression-free survival (PFS). This refers to the time a person lives without the disease worsening — in essence, how long they spend feeling well without needing additional treatment.
People who achieve uMRD typically have a longer PFS than those with detectable MRD, says Cloe, even if pathologists can only detect leukemia cells with highly sensitive MRD tests.
That’s because when treatment reduces the number of leukemia cells to levels so low that even highly sensitive tests can’t detect them, disease-worsening cell growth in any remaining cells generally takes significantly longer, says McCloskey.
In fact, in one large analysis of nearly 2,800 people with CLL, about 92 percent of people who achieved uMRD were living without disease progression at two years, compared with about 75 percent of those who had not achieved uMRD.
Guidance for Treatment Decisions
Achieving uMRD has become a primary goal of modern, fixed-duration therapies. Unlike continuous therapies, which a person takes indefinitely to control CLL, fixed-duration treatments are taken for a set period and then stopped.
For many people, achieving uMRD gives a care team confidence that treatment has worked well enough to safely stop fixed-duration treatments as planned, says McCloskey.
After achieving uMRD on fixed-duration CLL treatment, many people can enjoy a treatment-free period without the ongoing side effects, costs, and routine of taking daily medication.
Monitoring remains vital after finishing fixed-duration treatment and achieving uMRD. For people on fixed-duration therapies, a cancer care team will typically check MRD every three to six months during active treatment. Testing might take place every 6 to 12 months once therapy stops, as this can help your cancer care team detect any early signs of returning (or relapsing) CLL before symptoms develop, says McCloskey. He adds that people on continuous therapies don’t usually undergo routine MRD testing.
What to Know After Achieving uMRD
Achieving uMRD is a significant milestone that opens a door to recovery, but it doesn’t mean that your CLL has been completely cured. “Undetectable” means that the most sensitive tests available to modern medicine can’t find any leukemia cells, but it doesn’t necessarily mean that the CLL treatment has eliminated every leukemia cell in your body, McCloskey says. A very small number of dormant leukemia cells may still be present and could become active again in the future. This is why a leukemia care team will still regularly monitor people after they achieve uMRD.
McCloskey suggests that immediate treatment isn’t always necessary for people who develop detectable MRD after having achieved uMRD. Instead, any results showing new MRD serve as early warnings that your healthcare team can use to monitor the disease more closely. They’ll consider your MRD results along with your symptoms, blood counts, and other factors before deciding whether your treatment plan needs changing.
FAQ
1Is uMRD the same as remission?
No. Remission means routine tests don’t show any sign of the disease, and you have no symptoms of CLL. Undetectable minimal residual disease is a deeper level of remission, meaning highly sensitive tests can’t find any CLL cells.
2Does uMRD mean I am cured of CLL?
Although achieving uMRD is one of the best possible responses to CLL treatment, it isn’t considered a cure. Some leukemia cells may still be present at levels too low for even highly sensitive tests to detect.
3What if I don’t achieve uMRD on fixed-duration CLL treatment?
With fixed-duration treatments, having a small amount of detectable disease left doesn’t mean the treatment wasn’t successful. Your MRD result is just one piece of information that your care team uses to guide your care.
4What if I don’t achieve uMRD on continuous therapy?
Not achieving uMRD doesn’t mean your treatment failed. For people taking continuous therapies, the goal is long-term disease control, not necessarily uMRD.
5How often will my uMRD status be checked?
For most people on fixed-duration therapy, MRD checks occur every three to six months. Periodic monitoring may continue after treatment ends. People on continuous therapies don’t usually have routine MRD testing.
Resources We Trust
- Cleveland Clinic: Flow Cytometry
- Mayo Clinic: What Recovery Looks Like for Chronic Lymphocytic Leukemia
- CLL Society: Measurable Residual Disease (MRD)
- Association of Cancer Care Centers: MRD Testing in Chronic Lymphocytic Leukemia
- American Cancer Society: Tests for Chronic Lymphocytic Leukemia (CLL)
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
- Remission in Cancer. Cleveland Clinic. February 6, 2025.
- Song M et al. Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm. May 15, 2025.
- Rios-Olais FA et al. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis. JAMA Oncology. July 11, 2024.
- Benintende G et al. Measurable Residual Disease in Chronic Lymphocytic Leukemia. Frontiers in Oncology. February 13, 2023.
- Flow Cytometry. Cleveland Clinic. August 1, 2024.
- Rahmani A et al. Single-molecule flow cytometry. BioRxiv. August 26, 2025.
- Satam H et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology. July 12, 2023.
- Uchiyama T et al. Measurable Residual Disease in the Treatment of Chronic Lymphocytic Leukemia. Journal of Clinical and Experimental Hematopathology. November 4, 2020.
- Urso A et al. Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs. Cancers. July 31, 2024.
- Gyawali B et al. Progression-Free Survival: It Is Time for a New Name. The Lancet Oncology. March 2022.
- Munir T et al. Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. The New England Journal of Medicine. July 15, 2025.
- Youngblood Gregory S. Chronic Lymphocytic Leukemia (CLL): Understanding the Difference Between Fixed Duration and Continuous Treatment. Mayo Clinic. March 28, 2025.
- Munir T et al. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. The New England Journal of Medicine. December 10, 2023.
- Wierda WG et al. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026. Journal of the National Comprehensive Cancer Network. March 2026.
- Jain N et al. Is CLL Curable? HemaSphere. February 24, 2026.
- Measurable Residual Disease (MRD). CLL Society.
Meet Our Experts
Tingting Tan, MD, PhD
Medical Reviewer
Tingting Tan, MD, PhD, is a medical oncologist at City of Hope National Medical Center.
Dr. Tan's research has been published in multiple medical and scientific journals, including...
Maggie Aime, MSN, RN
Author
Maggie Aime is a registered nurse with over 25 years of healthcare experience, who brings medical topics to life through informative and inspiring content. Her extensive nursing ba...